- Home
- ICU vs ENLV Comparison
ICU vs ENLV Comparison
Compare ICU & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- ENLV
- Stock Information
- Founded
- ICU 2018
- ENLV 2005
- Country
- ICU United States
- ENLV Israel
- Employees
- ICU N/A
- ENLV N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- ENLV Health Care
- Exchange
- ICU Nasdaq
- ENLV Nasdaq
- Market Cap
- ICU 20.3M
- ENLV 23.7M
- IPO Year
- ICU N/A
- ENLV 1995
- Fundamental
- Price
- ICU $0.80
- ENLV $1.05
- Analyst Decision
- ICU
- ENLV Strong Buy
- Analyst Count
- ICU 0
- ENLV 2
- Target Price
- ICU N/A
- ENLV $10.00
- AVG Volume (30 Days)
- ICU 1.9M
- ENLV 1.3M
- Earning Date
- ICU 08-13-2025
- ENLV 09-02-2025
- Dividend Yield
- ICU N/A
- ENLV N/A
- EPS Growth
- ICU N/A
- ENLV N/A
- EPS
- ICU N/A
- ENLV N/A
- Revenue
- ICU $766,000.00
- ENLV N/A
- Revenue This Year
- ICU $754.07
- ENLV N/A
- Revenue Next Year
- ICU $100.09
- ENLV N/A
- P/E Ratio
- ICU N/A
- ENLV N/A
- Revenue Growth
- ICU N/A
- ENLV N/A
- 52 Week Low
- ICU $0.31
- ENLV $0.81
- 52 Week High
- ICU $6.65
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- ICU 53.18
- ENLV 39.24
- Support Level
- ICU $0.76
- ENLV $1.02
- Resistance Level
- ICU $0.81
- ENLV $2.10
- Average True Range (ATR)
- ICU 0.07
- ENLV 0.20
- MACD
- ICU 0.01
- ENLV -0.07
- Stochastic Oscillator
- ICU 53.69
- ENLV 6.25
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.